Bioelectronics Corp
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that pro… Read more
Bioelectronics Corp (BIEL) - Net Assets
Latest net assets as of March 2023: $-15.96 Million USD
Based on the latest financial reports, Bioelectronics Corp (BIEL) has net assets worth $-15.96 Million USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($170.37K) and total liabilities ($16.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-15.96 Million |
| % of Total Assets | -9370.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Bioelectronics Corp - Net Assets Trend (2013–2024)
This chart illustrates how Bioelectronics Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bioelectronics Corp (2013–2024)
The table below shows the annual net assets of Bioelectronics Corp from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-17.41 Million | -5.65% |
| 2023-12-31 | $-16.48 Million | -4.59% |
| 2022-12-31 | $-15.76 Million | -4.22% |
| 2021-12-31 | $-15.12 Million | +0.03% |
| 2020-12-31 | $-15.12 Million | -3.76% |
| 2019-12-31 | $-14.57 Million | -11.92% |
| 2018-12-31 | $-13.02 Million | -21.88% |
| 2017-12-31 | $-10.68 Million | -9.46% |
| 2016-12-31 | $-9.76 Million | -10.23% |
| 2015-12-31 | $-8.86 Million | -8.68% |
| 2014-12-31 | $-8.15 Million | -8.06% |
| 2013-12-31 | $-7.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioelectronics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1834465100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $23.34 Million | % |
| Total Equity | $-17.41 Million | 100.00% |
Bioelectronics Corp Competitors by Market Cap
The table below lists competitors of Bioelectronics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Il2m International Corp
PINK:ILIM
|
$2.76 |
|
Maxx Sports TV Inc
PINK:AMXX
|
$2.78 |
|
Founders Bay Holdings
PINK:FDBH
|
$2.79 |
|
GIB Capital Group Inc
PINK:GIBX
|
$2.79 |
|
Covista Communications Inc
PINK:CVST
|
$2.74 |
|
Astra Veda Corporation
PINK:ASTA
|
$2.74 |
|
EQM Technologies & Energy Inc
PINK:EQTE
|
$2.74 |
|
Dragon Capital Grp
PINK:DRGV
|
$2.73 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioelectronics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -16,478,418 to -17,409,069, a change of -930,651.
- Net loss of 930,650 reduced equity.
- Other factors decreased equity by 1.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-930.65K | -5.35% |
| Other Changes | $-1.00 | -0.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Bioelectronics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $0.00 | $0.00 | x |
| 2015-12-31 | $0.00 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
| 2024-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioelectronics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -187.62%
- • Asset Turnover: 11.45x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -367.48% | 0.75x | 0.00x | $-1.69 Million |
| 2014 | 0.00% | -207.56% | 1.86x | 0.00x | $-1.86 Million |
| 2015 | 0.00% | -104.73% | 2.34x | 0.00x | $-1.56 Million |
| 2016 | 0.00% | -100.81% | 2.93x | 0.00x | $-1.13 Million |
| 2017 | 0.00% | -120.13% | 3.51x | 0.00x | $-1.05 Million |
| 2018 | 0.00% | -285.73% | 2.23x | 0.00x | $-1.69 Million |
| 2019 | 0.00% | -246.91% | 2.73x | 0.00x | $-867.81K |
| 2020 | 0.00% | -139.80% | 1.95x | 0.00x | $352.49K |
| 2021 | 0.00% | -18.01% | 19.19x | 0.00x | $1.22 Million |
| 2022 | 0.00% | -110.96% | 2.83x | 0.00x | $790.65K |
| 2023 | 0.00% | -101.13% | 4.95x | 0.00x | $925.03K |
| 2024 | 0.00% | -187.62% | 11.45x | 0.00x | $810.26K |
Industry Comparison
This section compares Bioelectronics Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioelectronics Corp (BIEL) | $-15.96 Million | 0.00% | N/A | $2.75 |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |